Bio-Rad Laboratories Management
Management criteria checks 4/4
Bio-Rad Laboratories' CEO is Norman Schwartz, appointed in Jan 2003, has a tenure of 23.42 years. total yearly compensation is $8.00M, comprised of 13.6% salary and 86.4% bonuses, including company stock and options. directly owns 6.36% of the company’s shares, worth $499.74M. The average tenure of the management team and the board of directors is 2.3 years and 9.2 years respectively.
Key information
Norman Schwartz
Chief executive officer
US$8.0m
Total compensation
| CEO salary percentage | 13.63% |
| CEO tenure | 23.4yrs |
| CEO ownership | 6.4% |
| Management average tenure | 2.3yrs |
| Board average tenure | 9.2yrs |
Recent management updates
Recent updates
Narrative Update • Jun 04
BIO: Activist Pressure And Buybacks Will Shape Future Value Realization
Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.
Narrative Update • May 15
BIO: Share Repurchases Will Support Future Upside Despite Lower Margin Outlook
Analysts have trimmed their price target on Bio-Rad Laboratories from $321.25 to $293.00, reflecting updated views on growth, margins, discount rate, and future P/E assumptions. What's in the News From January 1, 2026 to March 31, 2026, Bio-Rad Laboratories repurchased 176,257 shares for US$47.42 million, equal to 0.65% of its shares.Narrative Update • Apr 29
BIO: Completed Buybacks And Intangible Impairment Will Support Future Upside
Analysts maintained their $320.00 price target for Bio-Rad Laboratories, making only minor adjustments to assumptions for discount rate, revenue, profit margin, and future P/E ratio to support this unchanged outlook. What's in the News Reported impairment charges of purchased intangibles and related items of $172.8 million for the fourth quarter ended December 31, 2025 (Key Developments).Narrative Update • Apr 15
BIO: Buybacks And Intangible Impairment Will Shape Balanced Forward Expectations
Analysts have reset their price target on Bio-Rad Laboratories from $375 to $320, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43 million under the buyback program announced on July 20, 2023 (Key Developments).Narrative Update • Mar 31
BIO: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Bio-Rad Laboratories from $348.00 to $321.25, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that result in a slightly more conservative valuation framework. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback that was announced on July 20, 2023 (Key Developments).Narrative Update • Mar 17
BIO: Share Repurchases And Intangible Impairment Will Shape Future Upside
Analysts have maintained their $375.00 price target for Bio-Rad Laboratories, citing only minor adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated model inputs rather than a change in their overall view. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).Narrative Update • Mar 03
BIO: Share Repurchases And Margin Outlook Will Support Future Upside
Analysts have maintained their price target for Bio-Rad Laboratories at $375, citing updated assumptions that include slightly higher revenue, improved profit margins, and a lower future P/E multiple, which together support the unchanged assessment of fair value. What's in the News From October 1, 2025 to December 31, 2025, Bio-Rad Laboratories reported no additional share repurchases, with 0 shares bought for $0, under its existing buyback program (Key Developments).Narrative Update • Feb 17
BIO: Share Repurchases Will Support Future Upside Despite Impairment Charges
Analysts are keeping their price target for Bio-Rad Laboratories steady at $375, with updated assumptions that include a slightly higher discount rate, a higher revenue growth outlook, a lower profit margin, and a higher future P/E multiple to reflect their latest view of the risk and return profile. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of the company, for a total of US$715.43 million under the buyback announced on July 20, 2023 (Key Developments).
Narrative Update • Feb 03
BIO: Fair Outlook Will Balance Richer Margins Against Higher Required Returns
Analysts have lifted their price target on Bio-Rad Laboratories from US$265 to US$325, reflecting updated views on slightly different growth assumptions, a higher projected profit margin, and an adjusted future P/E multiple. Valuation Changes Fair Value: updated from US$265 to US$325, indicating a higher implied valuation level.Seeking Alpha • Jan 22
Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth
Summary Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the latter's bioprocessing business is looking better of late. Management's guidance has been volatile, with 2025 core revenue growth targets fluctuating from 2.5% to near zero, then modestly rebounding. ddPCR is a bright spot, but broader revenue growth remains constrained; I see fair value at $338–$390, with rerating contingent on sustained growth. Read the full article on Seeking AlphaNarrative Update • Jan 20
BIO: Share Buybacks And Oncology Assay Partnership Will Drive Future Upside
Analysts have kept their price target for Bio-Rad Laboratories broadly steady at about US$375.00, reflecting only slight adjustments to modeled discount rate, revenue growth, profit margin, and future P/E assumptions in their updated views. What's in the News From July 1, 2025 to September 30, 2025, Bio-Rad repurchased 212,578 shares, about 0.79% of its shares, for US$52.83 million under its existing buyback program.Analysis Article • Jan 06
Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Key Insights Bio-Rad Laboratories' estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Current...Narrative Update • Jan 06
BIO: Share Buybacks And Oncology Partnership Will Support Future Upside
Analysts have lowered their price target on Bio-Rad Laboratories from US$437 to US$375, based on updated assumptions that combine more moderate revenue growth expectations with a slightly higher discount rate and a lower future P/E, partially offset by a higher projected profit margin. What's in the News Completed share repurchase of 2,614,132 shares, or 9.26% of the company, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).Narrative Update • Dec 14
BIO: Share Repurchase Will Drive Attractive Shareholder Returns Ahead
Narrative Update on Bio-Rad Laboratories Analysts have reaffirmed their conviction in Bio-Rad Laboratories, with the price target effectively unchanged at approximately 348 dollars. Modest tweaks to the discount rate, long-term revenue growth, profit margin, and future valuation assumptions largely offset one another in updated models.Narrative Update • Nov 28
BIO: Share Repurchase and Expanded Partnership Will Shape Performance in Coming Quarters
Analysts have maintained their price target for Bio-Rad Laboratories at $348.00, noting only minor adjustments to revenue growth and profit margin expectations this quarter. What's in the News Bio-Rad Laboratories completed the repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for $715.43 million under a buyback program announced in July 2023.Narrative Update • Nov 14
BIO: Share Repurchase and Expanded Partnerships Will Influence Future Performance
Analysts have raised their price target for Bio-Rad Laboratories from $324 to $348. They cite updated financial assumptions as well as small shifts in projected growth rates and profitability.Narrative Update • Oct 30
BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook
Analysts have raised their price target for Bio-Rad Laboratories from $310 to $324, reflecting updated profit margin estimates. These changes more than offset slightly lower revenue growth expectations.Narrative Update • Sep 28
Molecular Diagnostics Expansion Will Unlock Potential While Cost Challenges Persist
The decline in Bio-Rad Laboratories’ consensus price target to $310.00 primarily reflects lower future P/E and revenue growth expectations. What's in the News Completed buyback of 2,401,554 shares (8.47% of outstanding) for $662.6 million under program announced July 2023.Analysis Article • Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results
Investors in Bio-Rad Laboratories, Inc. ( NYSE:BIO ) had a good week, as its shares rose 7.7% to close at US$285...Analysis Article • Jul 14
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Narrative • May 13
Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics
Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.Seeking Alpha • Jan 29
Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential
Summary Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin leverage over the long term, and there are only a handful of meaningful revenue drivers with above-average potential. I believe BIO management has long been too conservative and unfocused with its R&D spending, but recent commentary suggests that growth potential and ROI will play a bigger role going forward. Bio-Rad's stake in Sartorius remains a significant store of value, but management's long-term plans remain unclear. While undervalued and having potential for longer-term growth upside, I remain cautious due to management and strategic concerns, as well as a large reliance on Sartorius to drive overall value. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Summary Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net sales are expected to decline in 2024. Valuing Bio-Rad using a discounted cash flow model indicates that the BIO stock is overvalued by 20.10%. Read the full article on Seeking AlphaSeeking Alpha • Sep 23
Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Summary Bio-Rad Laboratories is buying back a considerable amount of its own stock given the shares' current valuation and growth prospects. Profits and sales are expected to rebound in FY2025. A fuller look at Bio-Rad Laboratories is provided in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jul 14
Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Summary Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research and clinical diagnostics products. The company's stock has been underperforming due to various pressures, including its position in Sartorius AG. Despite potential catalysts like product launches, the stock is considered overvalued with weak returns on capital and declining margins. Read the full article on Seeking AlphaSeeking Alpha • Apr 14
Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Summary Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the life sciences space have been challenging, driving, double-digit declines in Bio-Rad's Life Sciences segment, and neither biopharma nor academic/government budgets look great for 2024. Bio-Rad's holdings in Sartorius bring significant value to the company, but Sartorius shares have sold off considerably since the bioproduction bubble popped and investor enthusiasm has faded. There's an interesting some-of-the-parts story here, particularly if bioproduction growth resumes after a period of capacity digestion, but it's hard to love Bio-Rad on a standalone basis. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$169m |
| Dec 31 2025 | US$8m | US$1m | US$760m |
| Sep 30 2025 | n/a | n/a | -US$676m |
| Jun 30 2025 | n/a | n/a | US$319m |
| Mar 31 2025 | n/a | n/a | -US$2b |
| Dec 31 2024 | US$8m | US$1m | -US$2b |
| Sep 30 2024 | n/a | n/a | -US$779m |
| Jun 30 2024 | n/a | n/a | -US$1b |
| Mar 31 2024 | n/a | n/a | -US$322m |
| Dec 31 2023 | US$7m | US$1m | -US$637m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$428m |
| Mar 31 2023 | n/a | n/a | -US$191m |
| Dec 31 2022 | US$8m | US$1m | -US$4b |
| Sep 30 2022 | n/a | n/a | -US$6b |
| Jun 30 2022 | n/a | n/a | -US$2b |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$9m | US$988k | US$4b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$8m | US$987k | US$4b |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$2b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$7m | US$950k | US$2b |
Compensation vs Market: Norman's total compensation ($USD8.00M) is about average for companies of similar size in the US market ($USD8.38M).
Compensation vs Earnings: Norman's compensation has been consistent with company performance over the past year.
CEO
Norman Schwartz (76 yo)
23.4yrs
Tenure
US$7,995,841
Compensation
Mr. Norman D. Schwartz has been the Chief Executive Officer of Bio-Rad Laboratories, Inc. since January 1, 2003 and has been its Chairman since 2012. Mr. Schwartz was Principal Financial Officer of Bio-Rad...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 23.4yrs | US$8.00m | 6.36% $ 499.7m | |
| President & COO | 1.8yrs | US$3.68m | 0.0034% $ 269.6k | |
| Executive VP & CFO | 2.2yrs | US$2.99m | 0.0096% $ 753.1k | |
| Executive VP & President of Life Science Group | no data | US$2.61m | 0.0019% $ 150.1k | |
| Executive Vice President of Global Commercial Operations | less than a year | US$2.99m | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP and Chief Compliance & Privacy Officer | no data | no data | no data | |
| Executive VP | 2.4yrs | no data | 0.0028% $ 220.1k | |
| Executive Vice President of Global Human Resources | no data | no data | no data | |
| Executive Vice President of Global Commercial Operations | 11.5yrs | US$2.24m | 0.031% $ 2.4m | |
| Senior Vice President of Global Technology & Systems | no data | no data | no data | |
| Senior Vice President of Marketing at Life Science Group | no data | no data | no data |
2.3yrs
Average Tenure
55yo
Average Age
Experienced Management: BIO's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 31.4yrs | US$8.00m | 6.36% $ 499.7m | |
| Lead Independent Director | 9.2yrs | US$337.71k | 0.0045% $ 356.9k | |
| Independent Director | 9.2yrs | US$324.71k | 0.0027% $ 209.9k | |
| Independent Director | 9.2yrs | US$309.71k | 0.0027% $ 209.9k | |
| Independent Director | 9.2yrs | US$329.71k | 0.0027% $ 209.9k | |
| Director | 4.2yrs | no data | 0.020% $ 1.6m |
9.2yrs
Average Tenure
67.5yo
Average Age
Experienced Board: BIO's board of directors are considered experienced (9.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 05:47 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bio-Rad Laboratories, Inc. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jon Wood | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |
| Patrick Donnelly | Citigroup Inc |